CCT369260

Cat. No.: HY-129188

Molecular Formula: $C_{24}H_{31}ClF_2N_6O_2$

Molecular Weight: 508.99

Target: Bcl-2 Family

Pathway: Apoptosis

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 300 mg/mL (589.40 mM; Need ultrasonic)

Preparing Stock Solutions

Concentration \ Solvent \ Mass	1 mg	5 mg	10 mg
1 mM	1.9647 mL	9.8234 mL	19.6468 mL
5 mM	0.3929 mL	1.9647 mL	3.9294 mL
10 mM	0.1965 mL	0.9823 mL	1.9647 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

CCT369260 (compound 1) is an orally avtive B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity. CCT369260 (compound 1) exhibits an IC_{50} of 520 nM[1].

IC_{50} & Target

IC50: 520 nM (BCL6)[1].

In Vivo

CCT369260 (compound 1, 15 mg/kg, po, single dose) significantly inhibits BCL6 in OCI-Ly1 DLBCL xenograft model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	OCI-Ly1 DLBCL xenograft model (female SCID mice)[1].
Dosage:	15 mg/kg.
Administration:	PO, single dose.
Result:	Decreased the levels of BCL6 in the tumor observed up to 10 h after administration.

Animal Model:	Female Balb/C mice[1].
Dosage:	1 mg/kg iv and 5 mg/kg po (Pharmacokinetic Analysis).
Administration:	IV and PO
Result:	Demonstrated moderate clearance (CL 20 mL min^{-1} kg^{-1}) with mean oral bioavailability of 54%.

REFERENCES

[1]. Benjamin R Bellenie, et al. Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders. J Med Chem. 2020 Apr 23;63(8):4047-4068.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA